Atlanta – Wednesday experts recommend a new combination shot as an alternative to the expansion of RSV vaccines for adults and to protect adolescents from meningitis for adults.
Advisory Committee on vaccination practice also voted for a shot to protect travelers from a mosquito -carried illness called Chikungunya.
However, it is not clear who will decide whether to accept these recommendations.
The 15-member expert panel recommends the director of the disease control and resistance center on how to use regulatory-clean vaccines. CDC directors almost always approve the recommendations.
The Trump administration named Susan Monarez as the acting CDC director in January and chose him to lead the agency last month. However, while waiting for the Senate confirmation, he has largely recovered himself from the federal law around the vacancies, and two CDC officials spoke on condition of anonymity because they were not authorized to discuss the issues and feared to be dismissed.
This means that the recommendation of any committee made on Wednesday can move to US Health Secretary Robert F. Kennedy Jr., the top voices of the anti -US movement.
A department spokesman for the Department of Health and Human Services told the Associated Press that he was investigating how to decide on the recommendations of the agency panel.
Wednesday was those recommendations:
– 50 to 59 people should be able to get vaccine against respiratory cincitial virus, including heart disease, diabetes and chronic barrier pulmonary disorders.
– A new combination shot made by GSK is the approval of a new combination shot that protects from five strains with a strain with a strain as a result of outbreaks in college campuses. It will join other products that also target germs.
– adding a second chikungunya vaccine to Americans of 12 years of age or older who are traveling to countries where outbreaks are occurring. About 100 to 200 cases are reported among US travelers annually.
– To add a new alert to the old chikungunya vaccine that is weak but use live viruses: 65 or older people should consider the risk of the convenience of that version of the shot, the panel said. The alert was added to the investigation of six reports of panel members of 655 years or older – most of them with other treatment problems – who were ill in the heart or brain symptoms in less than a week of vaccination. The investigation continues.
___
Associated Press Health and Science Department has received the support of the Science and Educational Media Group and Robert Wood Johnson Foundation of the Hughes Medical Institute. AP is the sole responsible for all content.
Leave a Reply